Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
about
A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases.[Adverse ocular effects of vaccinations].An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.Influenza vaccines: Evaluation of the safety profile.Adjuvanted influenza vaccines
P2860
Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@ast
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@en
type
label
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@ast
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@en
prefLabel
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@ast
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@en
P2093
P2860
P356
P1476
Phase II, randomized, open, co ...... at 24 months post-vaccination.
@en
P2093
Angels Jubert-Rosich
Carline Vanden Abeele
Isabel Ubeda
Josep Marès
José-María Baldó
Maria Victoria Planelles-Catarino
María Garcés-Sánchez
Maurice Teko
Paul Gillard
Philippe Moris
P2860
P356
10.1111/IRV.12295
P577
2015-02-05T00:00:00Z